Two-year, clinically focused training with extensive exposure across pediatric oncology (leukemia/lymphoma, solid tumor, neuro-oncology, cancer genetics, new agents/innovative therapies), hematology (hemoglobinopathies, marrow failure/MDS, thrombosis/hemostasis, general heme), and bone marrow transplantation & cellular therapy. Additional training spans hematopathology (morphology, flow, cytogenetics, molecular genetics, transfusion/coagulation), adult hematology, radiation oncology, and palliative care. Education includes inpatient/outpatient care, protected weekly Academic Half-Days, continuity clinics, subspecialty rounds, lectures, and seminars. The second year depends on successful completion of the first.
Eligibility Criteria:
-
International Medical Graduates with Certification in General Pediatrics.
-
At least one year of prior work and/or training in Paediatric Hematology/Oncology.
Funding Details:
-
Fully funded for the duration of the two-year program (stipend/benefit amounts not specified).
-
Clinical duties include outpatient and inpatient care plus on-call coverage for general hem/onc and BMT/cellular therapy.
Deadline:
-
Applications are currently closed. The next cycle opens January 1, 2026 for the July 1, 2027 – June 30, 2028 academic year.
-
Key dates (2026–2028 cohort):
-
Application opens: January 1, 2026
-
Submission deadline: April 30, 2026
-
Committee review: May – July 2026
-
Virtual interviews: July – September 2026
-
Decisions: September 2026 (email notification; offer letters follow)
-
Where to Go for Further Information: